AlzChem Group AG
ALZCF
Other OTC223.25
USD
- -
- -
AlzChem Group AG
ALZCF
(Other OTC)
Recent
price
223.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AlzChem Group AG operates as a global chemical enterprise, engaging in the development, manufacturing, and distribution of diverse chemical products across Germany, the broader European Union, Asia, the NAFTA region, and other international markets. The company’s operations are structured into three key areas: Specialty Chemicals, Basics & Intermediates, and Other & Holding. Within its Specialty Chemicals division, AlzChem offers an array of high-value solutions. These include dietary supplements like Creapure®, Creavitalis®, and LIVADUR®, along with nutritional feed additives such as Creamino® and the recently introduced Eminex® for animal nutrition and climate protection. The portfolio also encompasses pharmaceutical raw materials under the Bioselect® brand, epoxy resin hardeners branded DYHARD®, and silicon nitride marketed as SILZOT® for advanced ceramics and electronics. Further specialty offerings span technical gases, agricultural products including the PERLKA® fertilizer, ALZOGUR® germicide for livestock, plant growth regulators like Dormex® and Sitofex®, and BREAK-THRU® plant protection additives, alongside nitroguanidine for defense applications. The Basics & Intermediates segment focuses on essential chemical precursors, derived from the calcium carbide/calcium cyanamide (NCN) chain, including dicyandiamide, guanidine, guanamines, and other related compounds. The Other & Holding segment provides vital chemical park services and administrative functions. Founded in 1908 and based in Trostberg, Germany, AlzChem maintains a vertically integrated production network that enables flexible responses to market demands and fosters innovation. The company strategically concentrates on high-margin specialty chemicals, aligning its research and development with global megatrends such as human and animal nutrition, health, renewable energies, and sustainable agriculture. This focus contributed to a significant increase in EBITDA during the first nine months of 2025, with strong performance in its creatine business and custom manufacturing, leading to a confirmed positive outlook for the year. Recent developments include a partnership with Ehrmann for high-protein creatine products in October 2025 and the inauguration of a new training center. For the fiscal year 2024, AlzChem achieved record EBITDA and saw its shareholders approve a substantial dividend increase.
AlzChem Group AG (ALZCF) Q1 2026 Earnings Call Transcript
AlzChem Group AG (ALZCF) Q4 2025 Earnings Call Transcript